Excelerate Energy Announces First Quarter 2025 Earnings Conference Call Date

THE WOODLANDS, Texas--(BUSINESS WIRE)-- Excelerate Energy, Inc. (NYSE: EE) (the “Company” or “Excelerate”) will release its first quarter 2025 results on Wednesday, May 7, 2025, following the close of U.S. financial markets. The earnings release and presentation for the first quarter 2025 results will be available on the investor page of the Company’s website at www.excelerateenergy.com.

On Thursday, May 8, 2025, the Company’s management team will host a conference call for analysts and investors at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). The call will also be webcast live at www.excelerateenergy.com. An archived replay of the call and a copy of the presentation will be on the website following the call.

About Excelerate Energy:

Excelerate Energy, Inc. is a U.S.-based LNG company located in The Woodlands, Texas. Excelerate is changing the way the world accesses cleaner forms of energy by providing integrated services along the LNG value chain with an objective of delivering rapid-to-market and reliable LNG solutions to customers. The Company offers a full range of flexible regasification services from FSRUs to infrastructure development to LNG supply. Excelerate has a presence in Abu Dhabi, Antwerp, Boston, Buenos Aires, Chattogram, Dhaka, Doha, Dubai, Hanoi, Helsinki, London, Rio de Janeiro, Singapore, and Washington, DC. For more information, please visit www.excelerateenergy.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250408750231/en/

Investors:
Craig Hicks
Excelerate Energy
[email protected]

Media:
Stephen Pettibone / Frances Jeter
FGS Global
[email protected]
or
[email protected]

Source: Excelerate Energy, Inc.

You May Also Be Interested In

• Goldman Sachs Starts Excelerate Energy Inc (EE) at Buy
• Kawneer Selects Trevelino/Keller to Drive Integrated Marketing Strategy, Including Growth Marketing and Public Relations Support
• Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)